Pharmaceutical majors Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) have experienced a significant increase in their market value on Thursday, driven by the potential of their weight-loss...
Monday witnessed a significant rise in the stock price of DexCom, a leading provider of continuous glucose monitoring devices. The company's shares have surged by 36% since June 2022,...
An analyst from Raymond James maintained DexCom (NASDAQ: DXCM) at 'strong buy' with a price target of $131.00 from a prior price target of $154.00. Prior to this rating, DexCom had 19...
An analyst from UBS maintained DexCom (NASDAQ: DXCM) at 'buy' with a price target of $138.00 from a prior price target of $175.00. Prior to this rating, DexCom had 18 buy ratings, 2 hold...
DexCom , Inc. (DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Rimma Driscoll to its Board of Directors, effective August 24,...
An analyst from Baird maintained DexCom (NASDAQ: DXCM) at 'outperform' with a price target of $130.00 from a prior price target of $153.00. Prior to this rating, DexCom had 18 buy...
Investing.com -- The Dow closed higher Monday to wrap up a second-straight positive month for July after shrugging off a dip in health care as energy stocks racked up gains. The Dow Jones...
Investing.com -- The S&P 500 was largely unchanged Monday as falling health care stocks capped upside momentum on the final day of trade in July ahead of another wave of earnings this...
An analyst from Stifel maintained DexCom (NASDAQ: DXCM) at 'buy' with a price target of $155.00 from a prior price target of $140.00. Prior to this rating, DexCom had 18 buy ratings, 3...
An analyst from UBS maintained DexCom (NASDAQ: DXCM) at 'buy' with a price target of $175.00 from a prior price target of $152.00. Prior to this rating, DexCom had 18 buy ratings, 3 hold...
An analyst from JPMorgan maintained DexCom (NASDAQ: DXCM) at 'overweight' with a price target of $160.00 from a prior price target of $150.00. Prior to this rating, DexCom had 18 buy...
An analyst from Oppenheimer maintained DexCom (NASDAQ: DXCM) at 'outperform' with a price target of $150.00 from a prior price target of $135.00. Prior to this rating, DexCom had 18 buy...
An analyst from Jefferies maintained DexCom (NASDAQ: DXCM) at 'buy' with a price target of $155.00 from a prior price target of $150.00. Prior to this rating, DexCom had 18 buy ratings,...
An analyst from Canaccord Genuity maintained DexCom (NASDAQ: DXCM) at 'buy' with a price target of $150.00 from a prior price target of $135.00. Prior to this rating, DexCom had 18 buy...
An analyst from Raymond James maintained DexCom (NASDAQ: DXCM) at 'strong buy' with a price target of $154.00 from a prior price target of $140.00. Prior to this rating, DexCom had 18...
An analyst from Baird maintained DexCom (NASDAQ: DXCM) at 'outperform' with a price target of $153.00 from a prior price target of $145.00. Prior to this rating, DexCom had 18 buy...
An analyst from Wolfe Research maintained DexCom (NASDAQ: DXCM) at 'outperform' with a price target of $140.00 from a prior price target of $134.00. Prior to this rating, DexCom had 18...
Investing.com - DexCom (NASDAQ: DXCM) reported second quarter EPS of $0.34, $0.11 better than the analyst estimate of $0.23. Revenue for the quarter came in at $871.3M versus the consensus...
An analyst from Citi maintained DexCom (NASDAQ: DXCM) at 'buy' with a price target of $150.00 from a prior price target of $146.00. Prior to this rating, DexCom had 18 buy ratings, 2...
Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that Health Canada has approved the next-generation...
An analyst from Bernstein maintained DexCom (NASDAQ: DXCM) at 'outperform' with a price target of $150.00 from a prior price target of $145.00. Prior to this rating, DexCom had 17 buy...
An analyst from BTIG maintained DexCom (NASDAQ: DXCM) at 'buy' with a price target of $150.00 from a prior price target of $134.00. Prior to this rating, DexCom had 17 buy ratings, 3...
An analyst from Morgan Stanley initiated coverage of DexCom (NASDAQ: DXCM) at 'equalweight' with a price target of $131.00. Prior to this rating, DexCom had 18 buy ratings, 2 hold...
DexCom (DXCM) announced today the pricing of its offering of $1.1 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2028 (the “notes”) in a private placement to...
DexCom , Inc. (Nasdaq: DXCM) (“Dexcom”) announced today that it intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of Convertible...
A Barclays analyst maintained DexCom (NASDAQ: DXCM) at Equalweight and a price target of $115.00 from a prior price target of $110.00. Prior to this rating, DexCom had 17 buy ratings, 3...
A JPMorgan analyst maintained DexCom (NASDAQ: DXCM) at Overweight and a price target of $150.00 from a prior price target of $135.00. Prior to this rating, DexCom had 17 buy ratings, 3...
A BTIG analyst maintained DexCom (NASDAQ: DXCM) at Buy and a price target of $134.00 from a prior price target of $132.00. Prior to this rating, DexCom had 17 buy ratings, 3 hold ratings,...
Investing.com - DexCom (NASDAQ: DXCM) reported first quarter EPS of $0.17, $0.02 better than the analyst estimate of $0.15. Revenue for the quarter came in at $741.5M versus the consensus...
A Raymond James analyst upgraded DexCom (NASDAQ: DXCM) from Outperform to Strong Buy with a price target of $138.00 from a prior price target of $127.00. Prior to this rating, DexCom had 18...
An UBS analyst initiated new coverage DexCom (NASDAQ: DXCM) Buy rating and a price target of $142.00. Prior to this rating, DexCom had 16 buy ratings, 3 hold ratings, and 1 sell...
DexCom , Inc. (DXCM), today issued the following statement in response to speculation following the developments at Silicon Valley Bank, including a recent CNBC article:“Dexcom does not...
By Sam Boughedda DexCom Inc (NASDAQ:DXCM) shares are down more than 8% Monday afternoon after Abbott Laboratories (NYSE:ABT) announced that the U.S. Food and Drug Administration...
By Sam Boughedda DexCom Inc (NASDAQ:DXCM) shares jumped more than 6% Thursday after it was revealed that Medicare will cover continuous glucose monitors (CGMs) for a wider group of...
By Sam Boughedda Apple (NASDAQ:AAPL) believes it could eventually bring a non-invasive and continuous blood glucose monitoring product to market after hitting major milestones, Bloomberg...
DexCom (DXCM) reported Q4 EPS of $0.34, $0.07 better than the analyst estimate of $0.27. Revenue for the quarter came in at $815.2 million versus the consensus estimate of $809.35...
Investing.com - DexCom (NASDAQ: DXCM) reported fourth quarter EPS of $0.34, $0.07 better than the analyst estimate of $0.27. Revenue for the quarter came in at $815.2M versus the consensus...
By Yasin Ebrahim Investing.com -- The Dow gave up gains to close lower Monday, as falling health care and energy stocks offset tech strength in tech after Treasury yields slipped amid...
After-Hours Stock Movers: Amazon.com (NASDAQ:AMZN) 14% LOWER; {{erl-6435||reported Q3 EPS of $0.28, $0.06 better than the analyst estimate of $0.22. Revenue for the quarter came in at $127.1...
DexCom (DXCM) reported Q3 EPS of $0.28, $0.04 better than the analyst estimate of $0.24. Revenue for the quarter came in at $769.6 million versus the consensus estimate of $751.74...
By Investing.com Staff Shares of DexCom (NASDAQ:DXCM) are 8% higher in early trading Friday after Medicare issued a Local Coverage Decision (LCD) proposal on Thursday for continuous...
By Senad Karaahmetovic Citi analysts made a series of changes in the firm’s coverage of Medical Supplies and Technology ahead of the Q3 earnings season. Overall, they see...
By Sam Boughedda BofA Securities released a research paper to clients Monday outlining the firm's top ten U.S. ideas for the fourth quarter. The list includes nine Buys and one Underperform...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
